

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

**March 24, 2023**

Date of Report (Date of earliest event reported)

**BIOAFFINITY TECHNOLOGIES, INC.**

(Exact name of registrant as specified in its charter)

**Delaware**  
(State or other jurisdiction  
of incorporation)

**001-41463**  
(Commission  
File Number)

**46-5211056**  
(I.R.S. Employer  
Identification Number)

**22211 W Interstate 10  
Suite 1206  
San Antonio, Texas 78257  
(210) 698-5334**

(Address of principal executive offices and Registrant's telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, par value \$.007 per share	BIAF	The Nasdaq Stock Market LLC
Tradeable Warrants to purchase Common Stock	BIAFW	The Nasdaq Stock Market LLC

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

**Item 8.01. Other Events.**

Recent Press Release

On March 24, 2023, the Company issued a press release announcing that it will report its fourth-quarter financial results for the quarter ended December 31, 2022 after the market close on Friday, March 31, 2023. The Company also announced the details of a conference call scheduled for Monday, April 3, 2023, to discuss its fourth-quarter results. The press release is filed as Exhibit 99.1 to this Form 8-K and is incorporated herein by reference.

**Item 9.01 Financial Statements and Exhibits.**

(d) Exhibits.

Exhibit No.	Description
99.1	<a href="#">Press Release of bioAffinity Technologies, Inc., dated March 24, 2023.</a>
104	Cover Page Interactive Data File (embedded within the Inline XBRL document)

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

BIOAFFINITY TECHNOLOGIES, INC.

By: /s/ Maria Zannes

Maria Zannes

President and Chief Executive Officer

Dated: March 24, 2023

---



## News Release

### bioAffinity Technologies to Report Fourth Quarter 2022 Financial Results on March 31, 2023

*Conference Call scheduled on April 3, 2023, at 9 a.m. Eastern time*

**SAN ANTONIO, Texas (March 24, 2023)** – **bioAffinity Technologies, Inc. (NASDAQ: BIAF; BIAFW)** today announced it will report financial results for the three months ended December 31, 2022, on Friday, March 31, 2023, after the market close. The Company will host a conference call on Monday, April 3, 2023, at 9:00 a.m. Eastern time to discuss those results and answer questions.

**Event:** bioAffinity Technologies Fourth Quarter 2022 Financial Results  
**Date:** Monday, April 3, 2023  
**Time:** 9:00 a.m. EDT  
**Toll Free:** 1-877-270-2148  
**International:** 1-412-902-6510  
**Webcast:** [Webcast link](#)

A replay of the event will be available for 90 days at the webcast link above, which can also be found in the Investor Relations section of bioAffinity's website at [www.ir.bioaffinitytech.com](http://www.ir.bioaffinitytech.com).

#### About bioAffinity Technologies, Inc.

bioAffinity Technologies, Inc. addresses the need for non-invasive diagnosis of early-stage cancer and diseases of the lung and targeted cancer treatment. The Company's first product, **CyPath® Lung**, is a non-invasive test that has shown high sensitivity and specificity for the detection of early-stage lung cancer. CyPath® Lung is marketed as a Laboratory Developed Test (LDT) by **Precision Pathology Services**. OncoSelect Therapeutics, LLC, a subsidiary of bioAffinity Technologies, is advancing its discoveries shown in vitro to kill cancer cells without harm to normal cells. Research and optimization of the Company's platform technologies are conducted in its laboratories at The University of Texas at San Antonio. For more information, visit [www.bioaffinitytech.com](http://www.bioaffinitytech.com).

#### Forward-Looking Statements

This press release contains forward-looking statements, including statements regarding the anticipated use of proceeds from the Company's offering of common shares. Forward-looking statements can be identified by words such as "believes," "expects," "estimates," "intends," "may," "plans," "will" and similar expressions, or the negative of these words. Such forward-looking statements are based on facts and conditions as they exist at the time such statements are made and predictions as to future facts and conditions. Readers of this press release are cautioned not to place undue reliance on any forward-looking statements. The Company does not undertake any obligation to update any forward-looking statement relating to matters discussed in this press release, except as may be required by applicable securities laws.

#### Contacts

**bioAffinity Technologies**  
 Julie Anne Overton  
 Director of Communications  
[jao@bioaffinitytech.com](mailto:jao@bioaffinitytech.com)

**LHA Investor Relations**  
 Tirth T. Patel  
[tpatel@lhai.com](mailto:tpatel@lhai.com)

###